Milnacipran: A serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia syndrome

Formulary

Volumn 44, Issue 7, 2009, Pages 197-202

  Cios, Deborah A ^a   Kim, Julie E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CLONIDINE; DIGOXIN; DULOXETINE; HYDROCODONE; LITHIUM; MILNACIPRAN; NORADRENALIN; PLACEBO; SAVELLA; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

BLOOD PRESSURE; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FIBROMYALGIA; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; MIGRAINE; NAUSEA; ORTHOSTATIC HYPOTENSION; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

EID: 77951954339     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
2. Lawson K. Emerging pharmacological therapies for fibromyalgia. Curr Opin Investig Drugs. 2006; 7:631-636.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
4. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol. 2008;20:246-250.
5. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59:1279-1298.
6. Owen RT. Milnacipran hydrochloride: Its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2008;44:653-660.
7. Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006;7:637-642.
8. Gracely RH, Jensen K, Petzke F, et al. The effect of milnacipran on pain modulatory systems in fibromyalgia: An fMRI analysis [abstract]. Ann Rheum Dts. 2008;67(suppl 2):255.
9. Savella [package insert]. New York, NY: Forest Pharmaceuticals, Inc.; 2009.
10. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988-2004.
11. [erratum in Clin Ther. 2009;31:446]
12. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409.
13. [erratum in J Rheumatol. 2009;36:661]
14. Branco JC, Perrot S, Bragee G, et al. Milnacipran for the treatment of fibromyalgia syndrome: A European multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Ann Rheum Dts. 2008;67(suppl 2):251.
15. Vitton O, Gendreau M, Gendreau J, Kranzler R, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(suppl 1): S27-S35.
16. Gendreau RM, Thom MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.